211 
Market Cap
As of November 13, 2009: $1,456,000.00
Stock Chart
Peplin - 30 day Poll
Recent BLOGS About Peplin Add New
 |
Great to see Peplin acquired!
However I wonder if it is too cheap as at certain times they have had stock prices above $1 at an ea… Read more
|
Latest Company News
There are no news articles to display.
Website
Videos related to Peplin
Company Profile
Peplin was acquired by LEO Pharma for US$287.5m on 2 Sept. 2009
Peplin Inc. (PLI) is a pharmaceutical company focused on the development and commercialisation of medical dermatology products. The company has offices in Brisbane, Queensland and Emeryville, California and a manufacturing facility in Southport, Queensland. Peplin has a Phase 3 product and is a specialty pharmaceutical company. Peplin is currently developing PEP005 (ingenol mebutate), or PEP005, which is a novel compound derived from Euphorbia peplus, or E. peplus, a rapidly growing, readily-available plant, commonly referred to as petty spurge or radium weed. The sap of E. peplus has a long history of traditional use for a variety of conditions, including the topical self-treatment of various skin disorders, such as skin cancer and pre-cancerous skin lesions. Peplin has international patent coverage over its technologies.
Clinical areas include:
- Actinic (solar) Keratosis (AK) in Phase II trial
- Basal Cell Carcinoma (sBCC) in Phase II
- Some further compounds are also inside the comapny and in early development.
Cash on hand: $17.7M as of June 30th 2009
Upcoming events:
- 4Q 2009 Phase 3 Face and Scalp (REGION-IIa and REGION-IIb) plans to announce the REGION-II trial results.
Peplin Inc. (PLI) is a pharmaceutical company focused on the development and commercialisation of medical dermatology products. The company has offices in Brisbane, Queensland and Emeryville, California and a manufacturing facility in Southport, Queensland. Peplin has a Phase 3 product and is a specialty pharmaceutical company. Peplin is currently developing PEP005 (ingenol mebutate), or PEP005, which is a novel compound derived from Euphorbia peplus, or E. peplus, a rapidly growing, readily-available plant, commonly referred to as petty spurge or radium weed. The sap of E. peplus has a long history of traditional use for a variety of conditions, including the topical self-treatment of various skin disorders, such as skin cancer and pre-cancerous skin lesions. Peplin has international patent coverage over its technologies.
Clinical areas include:
- Actinic (solar) Keratosis (AK) in Phase II trial
- Basal Cell Carcinoma (sBCC) in Phase II
- Some further compounds are also inside the comapny and in early development.
Cash on hand: $17.7M as of June 30th 2009
Upcoming events:
- 4Q 2009 Phase 3 Face and Scalp (REGION-IIa and REGION-IIb) plans to announce the REGION-II trial results.
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use